Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains

被引:10
作者
Mayank [1 ]
Kaur, Navneet [2 ]
Singh, Narinder [1 ]
机构
[1] Indian Inst Technol Ropar, Dept Chem, Rupnagar 140001, Punjab, India
[2] Punjab Univ Chandigarh, Dept Chem, Chandigarh, Punjab, India
关键词
MOLECULAR-DYNAMICS; RAF/MEK/ERK PATHWAY; INHIBITORY-ACTIVITY; CANCER; DOCKING; INFORMATION; ANALOGS; TARGETS; ESCAPE; DESIGN;
D O I
10.1039/c8ib00095f
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in the BRAF gene are well known for their oncogenic effects. Point mutations in V599 are particularly oncogenic and are considered important for therapeutic purposes. Along with wild type, other V599 mutated BRAF variants viz. V599E, V599D and V599R are reported and crystals of the former two with inhibitor (BAY43-9006) are further detailed. Both wild-type and mutated BRAF forms show similar interaction patterns with BAY43-9006, but the 599th residue did not show any involvement in the interactions. Upon BAY43-9006 binding, kinase domains of both forms were found adopting essentially identical conformations. However, BAY43-9006 shows a varied activity profile in the case of the wild and V599E variant of the BRAF protein. Furthermore, MMGBSA binding energy results for all four BRAF variants, further revealed the importance of the 599th residue. In-depth analysis viz. molecular dynamics, residue correlation studies and residue interaction network (RIN) analyses were conducted, providing a deep insight into the 599th residue and its impact on the overall dynamics of BRAF protein. Our findings reveal that the mutated residue at the 599th position not only changed the BAY43-9006-BRAF binding behaviour but also produced a massive impact on the overall dynamic behaviour of the protein. The insights obtained herein could be of great relevance for designing new BRAF inhibitors aimed at getting ideal activity against all BRAF forms.
引用
收藏
页码:646 / 657
页数:12
相关论文
共 47 条
[21]   Development of a cyclin-dependent kinase inhibitor devoid of ABC transporterdependent drug resistance [J].
Kaliszczak, M. ;
Patel, H. ;
Kroll, S. H. B. ;
Carroll, L. ;
Smith, G. ;
Delaney, S. ;
Heathcote, D. A. ;
Bondke, A. ;
Fuchter, M. J. ;
Coombes, R. C. ;
Barrett, A. G. M. ;
Ali, S. ;
Aboagye, E. O. .
BRITISH JOURNAL OF CANCER, 2013, 109 (09) :2356-2367
[22]   The future of cancer treatment: immunomodulation, CARs and combination immunotherapy [J].
Khalil, Danny N. ;
Smith, Eric L. ;
Brentjens, Renier J. ;
Wolchok, Jedd D. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (05) :273-290
[23]   Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family [J].
Kinnings, Sarah L. ;
Jackson, Richard M. .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (02) :318-329
[24]   KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines [J].
Lavrado, Joao ;
Brito, Hugo ;
Borralho, Pedro M. ;
Ohnmacht, Stephan A. ;
Kim, Nam-Soon ;
Leitao, Clara ;
Pisco, Silvia ;
Gunaratnam, Mekala ;
Rodrigues, Cecilia M. P. ;
Moreira, Rui ;
Neidle, Stephen ;
Paulo, Alexandra .
SCIENTIFIC REPORTS, 2015, 5
[25]   Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring [J].
Lyne, Paul D. ;
Lamb, Michelle L. ;
Saeh, Jamal C. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (16) :4805-4808
[26]   RING: networking interacting residues, evolutionary information and energetics in protein structures [J].
Martin, Alberto J. M. ;
Vidotto, Michele ;
Boscariol, Filippo ;
Di Domenico, Tomas ;
Walsh, Ian ;
Tosatto, Silvio C. E. .
BIOINFORMATICS, 2011, 27 (14) :2003-2005
[27]   Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers [J].
Namba, H ;
Nakashima, M ;
Hayashi, T ;
Hayashida, N ;
Maeda, S ;
Rogounovitch, TI ;
Ohtsuru, A ;
Saenko, VA ;
Kanematsu, T ;
Yamashita, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4393-4397
[28]   Cell cycle proteins as promising targets in cancer therapy [J].
Otto, Tobias ;
Sicinski, Piotr .
NATURE REVIEWS CANCER, 2017, 17 (02) :93-115
[29]   Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation [J].
Pandey, Rajan Kumar ;
Kumbhar, Bajarang Vasant ;
Srivastava, Shubham ;
Malik, Ruchi ;
Sundar, Shyam ;
Kunwar, Ambarish ;
Prajapati, Vijay Kumar .
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2017, 35 (01) :141-158
[30]   Post-translational modification: nature's escape from genetic imprisonment and the basis for dynamic information encoding [J].
Prabakaran, Sudhakaran ;
Lippens, Guy ;
Steen, Hanno ;
Gunawardena, Jeremy .
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 2012, 4 (06) :565-583